Clinical effects of metformin in patients with nonobese type 2 diabetes

Journal of the Japan Diabetes Society

Volumn 52, Issue 1, 2009, Pages 1-6

  Hosokawa, Kazuhiro ^a,b   Meguro, Shu ^a   Funae, Osamu ^c   Murata, Chisato ^a   Katou, Kiyoe ^a   Mokubo, Atsuko ^a   Suzuki, Yoshihiko ^d   Anazawa, Sonoko ^a   Atsumi, Yosihito ^a   Matsuoka, Kempei ^a  

^a SAISEIKAI CENTRAL HOSPITAL   (Japan)

^b Hosokawa Clinic for Internal Medicine   (Japan)

^c Tokui Clinic for Internal Medicine   (Japan)

^d Hokendohjin Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 61749089270     PISSN: 0021437X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Johansen K (1999) Efficacy of metformin in the treatment of NIDDM meta-analysis. Diabetes Care 22: 33-37
2. Hermann LS, Schersten B, Bitzen PO, Kjellstroem T, Lindgaerde F, Melander A (1994) Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations: a double-blind controlled study. Diabetes Care 17: 1100-1109
3. DeFronzo RA, Goodman AM, the multicenter metformin study group (1995) Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 541-549
4. U.K. Prospective Diabetes Study Group (1995) U.K. prospective Diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 44: 1249-1258
5. Turner R, Cull C, Holman R (1996) United Kingdom Prospecitive Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124: 136-145
6. Dornan TL, Heller SR, Peck GM, Tattersall RB (1991) Double-blind evaluation of efficacy and tolerability of metformin in NIDDM. Diabetes Care 14: 342-344
7. Japanese source
8. Japanese source
9. Haupt E, Knick B, Koschinsky T, Liebermeister H, Schneider J, Hirche H (1991) Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabetes Metab 17: 224-231
10. UKPDS 28 (1998) a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated Type 2 diabetes. U.K. Prospective Diabetes Study Group Diabetes Care 21: 87-92
11. Fanghanel G, Sanchez-Reyes L, Trujille C, Sortes D, Espinosa-Campos J (1996) Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas. Diabtes Care 19: 1185-1189
12. Ong CR, Molyneaux LM, Constanntino MI, Twigg SM, Yue DK (2006) Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. Diabetes Care 29: 2361-2364
13. Clarke BF, Campbell IW (1977) Comparison of metformin and chlorpropamide in non-obese, maturity-onset diabetics uncontrolled by diet. Br Med J 2: 1576-1578
14. Iijima T, Sakamoto S, Nakajima Y, Toba T (2001) Efficacy of metformin in non-obese type 2 diabetic patients with secondary failure to sulfonylurea therapy. Gen Med 1: 11-16
15. Japanese source
16. Japanese source
17. DeFronzo RA, Barzilai N, Simonson DC (1991) Mechanism of metformin action in obese and lean non-insulin-dependent diabetes subjects. J Clin Endocrinol Metab 73: 1294-1301
18. Perriello G, Misericoidia P, Volpi E, Satucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB (1994) Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 43: 920-928
19. Nagi DK, Yudkin JS (1993) Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 16: 621-629
20. Nagasaka S, Aiso Y, Yoshizawa K, Ishibashi S (2004) Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabetic Med 21: 136-141
21. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman M, Goodyear LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174
22. Yatagai T, Nagasaka S, Taniguchi A, Fukushima M, Nakamura T, Kuroe A, Nakai Y, Ishibashi S (2003) Hypoadiponectinemia is associated with visceral fat accumulation and insulin resistance in Japanese men with type 2 diabetes mellitus. Metabolism 52: 1274-1278